Brief: Crispr Therapeutics And Sirius Therapeutics Announce Multi-Target Collaboration To Develop Novel Sirna Therapies

Crispr Therapeutics AG

19/05/2025 21:53

CRISPR Therapeutics AG CRSP.BN:

CRISPR THERAPEUTICS AND SIRIUS THERAPEUTICS ANNOUNCE MULTI-TARGET COLLABORATION TO DEVELOP NOVEL SIRNA THERAPIES

CRISPR THERAPEUTICS AG: WILL MAKE AN UPFRONT PAYMENT OF $25 MILLION IN CASH AND $70 MILLION IN EQUITY TO SIRIUS THERAPEUTICS

CRISPR THERAPEUTICS AG: ALSO HAS RIGHTS TO EXCLUSIVELY LICENSE UP TO TWO ADDITIONAL SIRNA PROGRAMS

CRISPR THERAPEUTICS AG - SRSD107 SHOWS >93% FXI REDUCTION IN PHASE 1 TRIAL

Source text: ID:nGNX4YpMYT

Further company coverage: CRSP.BN